Sue Dooley
Investor Relations
Replay available
Lumexa Imaging Holdings, Inc. (NASDAQ: LMRI) Q1 2026 earnings conference call, held 2026-05-12. Replay captured from the company's public earnings webcast.

Investor Relations
Chief Executive Officer
Chief Financial Officer
Analyst, Jefferies
Analyst, JP Morgan
Analyst, William Blair
Analyst, RJF
Analyst, Barclays
Analyst, Wells Fargo
Analyst, Deutsche Bank
Thank you for standing by, and welcome to Lumexa Imaging's first quarter 2026 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 11 on your telephone. If your question has been answered and you'd like to remove yourself from the queue, simply press star 1-1 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Sue Dooley from Lumexa Investor Relations. Please go ahead. Thank you, and hello, everyone. We appreciate you joining us today. Leading today's call are our Chief Executive Officer, Caitlin Zula, and Tony Martin, our CFO. Before we begin, I want to note that we'll be discussing non-GAAP financial measures we consider helpful in evaluating Lumexa's performance. You can find details of how these relate to our GAAP measures, along with reconciliations in the press release available on our website. We'll also be making forward-looking statements based on our current expectations and assumptions, which are subject to risks and uncertainties, including factors listed in our press release and in our various SEC filings. Actual results could differ materially, and we assume no obligation to update these forward-looking statements. With that, I'll turn the call over to Caitlin. Caitlin, please go ahead. Thanks, Sue. Thank you all for joining us today. In Q1, we delivered several meaningful achievements to kick off a year executing on our strategic priorities, which include driving strong same-center growth with an expanding mix of advanced modalities, targeting a record number of de novo openings, ensuring the successful ramp of newly opened cent...